GlassScriptPhysician profile
Saeed R Shaikh
NPI 1407828817
$13,909.18
in general payments reported to CMS, 2019-2025
19 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,665 · 2020: $1,011 · 2021: $412 · 2022: $1,789 · 2023: $2,324 · 2024: $2,141 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,378 · Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,377.86 |
| Food and Beverage | $2,653.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,889.28 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $3,798.65 | 2019-2025 | Mitraclip, Triclip, Xience V |
| Boston Scientific Corporation | $1,956.57 | 2019-2024 | Watchman Access System, Watchman Flx |
| Medtronic Vascular, INC. | $1,288.06 | 2019 | |
| Livanova USA, INC. | $876.41 | 2020 | |
| Medtronic, INC. | $261.34 | 2021-2023 | Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $161.16 | 2019-2024 | |
| Abiomed | $144.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Bard Peripheral Vascular, INC. | $117.74 | 2019 | |
| Medical Device Business Services, INC. | $58.51 | 2024 | Carto 3 |
| Astrazeneca Pharmaceuticals LP | $54.50 | 2019-2022 | |
| Pfizer INC. | $51.64 | 2019-2023 | |
| Terumo Medical Corporation | $39.27 | 2025 | Angio-Seal |
| Biosense Webster, INC. | $28.62 | 2021-2023 | Na |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.65 | 2021 | |
| Novo Nordisk INC | $22.50 | 2024 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $10.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.